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Introduction: 
Erythropoiesis- stimulating agents (ESAs) are widely used to in treating anaemia associated with 
renal failure. They are also now used perioperatively to reduce the use of allogeneic blood 
transfusions (ABTs) in patients undergoing surgery with anticipated high blood loss. Although they 
can reduce the risks associated with ABT and improve quality of life, the use of ESAs is still 
associated with adverse effects. 
Areas covered: 
A narrative review is provided on ESAs and a systematic review was has been conducted to 
examine the current evidence for the efficacy and safety of perioperative ESAs use. A search of 
PubMed and Medline databases was has been performed using a combination of search terms 
including erythropoietin, perioperative, surgical, safety and efficacy. 
Expert opinion: 
Current evidence supports the use of perioperative ESAs to reduce the need for ABT. However, 
large studies assessing safety in anaemic patients with chronic renal disease have found adverse 
effects including cardiovascular, stroke and thromboembolic events. The dosing strategies used[CE1]
have been varied and short term in comparison, to adequately assess whether these adverse effects
can be conferred onto the perioperative population. Future research needs to address the questions 
of optimal dosing strategies in order to maximisze the positive effects but alsoand minimisze 
adverse events. 
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1. Introduction 
Major complex surgical procedures may be associated with substantial intraoperative and/or post
operative blood loss. A significant number of patients that develop anaemia from blood loss will 
require allogeneic blood transfusions (ABTs) and this is more likely if preoperative anaemia is 
present –, a state that is not uncommon in certain surgical populations. Anaemia in itself can be 
harmful; in order to maintain systemic oxygen delivery, there is a compensatory increase in cardiac 
output. Even mild preoperative anaemia is independently associated with an increased risk of 30-
day morbidity and mortality and postoperative complication rates in patients undergoing major non-
cardiac surgery 1. 
Although blood transfusion, in the context of either severe anaemia or life-threatening 
haemorrhage, can improve oxygen delivery to various organs, its use is associated with a number of 
well-recogniszed risks and complications. These include infectious risks, as well as transfusion 
reactions, transfusion errors, immunological reactions and immune modulation 2, 3. The rise in 
hemoglobin (Hb) from blood transfusions are is not consistently associated with improvement in 
oxygen delivery or oxygen consumption. This may be due to the significantly altered properties of 
the stored blood, including the depletion of 2,3-DPG which causes a left shift of the oxygen 
dissociation curve, thus impairing the oxygen- deliveringy ability of red blood cells 4. 
The concerns regarding the adverse effects of ABT have prompted reviews of transfusion practices 
and the development of strategies to minimizse the need. These include the implementation of 
restrictive transfusion protocols, use of pharmacological and non-pharmacological measures to 
reduce blood loss, preoperative autologous blood donation for transfusion, perioperative cell 
salvage, and stimulation of preoperative erythropoiesis 5, 6. 
This review will focus on erythropoiesis- stimulating agents (ESAs) as a component of this patient 
haematological strategy[CE2]. First, it will provide a narrative review on erythropoietin, including its
history, formulations and regimens, is provided. Secondly, it will examine, in a semi-quantitative 
manner, the efficacy and safety of perioperative erythropoietin use is examined in a 
semiquantitative manner. 
1.1 AEetiology of preoperative anaemia 
In a US national audit of patients undergoing elective orthopaedic surgery, 35% of patients were 
found to have Hb levels < 13 g/dL at preadmission testing. Many are were [CE3]women and anemia 
in approximately one- third of these patients ahad beenre the result of iron deficiency, with the 
remaining being attributed to chronic inflammatory disease, chronic renal disease or unknown 
causes 7. 
Patients undergoing major surgery with anticipated high blood loss often have co-morbidities, 
underlying chronic disease processes as well as being of advanced age. Aging is increasingly being 
identified as a proinflammatory state. The anaemia of chronic disease is multifactorial but is 
thought to be immune -driven. Cytokines induce changes[CE4] in iron homeostasis, impaired the
proliferation of erythroid progenitor cells, and reduce circulating levels of erythropoietin and the 
life span of red blood cells. Increase uptake of iron by cells of the reticuloendothelial systems 
causes a diversion of iron away from the circulation. Erythropoiesis can be directly affected by the 
infiltration into bone marrow of microorganisms as well as tumour cells 8. Ongoing occult blood 
losses from gastrointestinal or urogenital cancers may also contribute. 
2. Erythropoietin and erythropoiesis-stimulating agents 
Erythropoietin is the primary regulator of erythropoiesis. It is a glycoprotein hormone naturally 
produced and secreted primarily by renal tubular cells with a minor hepatic contribution. Production 
is stimulated by tissue hypoxia or severe haemorrhagic stress, and erythropoietin binds to specific 
receptors on erythroid progenitor cells in the bone marrow. The ultimate effect is to increase 
erythropoiesis in an attempt to maintain oxygen delivery to vital organs. 
In 1977, human erythropoietin was successfully purified and characteriszed from the urine of 
patients with aplastic anaemia. In 1985, two groups of investigators independently cloned the 
human erythropoietin gene, identifying the corresponding nucleotide sequences 9. Erythropoietin 
for clinical use is now produced by recombinant DNA technology. The first human trials using 
recombinant human erythropoietin (rHuEPO), which is identical to the naturally occurring 
erythropoietin, examined its effectiveness in correcting anaemia of chronic renal disease. These 
initial results demonstrated that rHuEPO could increase the haemoglobinHb level, thus removing 
the need for regular blood transfusion and improving the quality of life in patients requiring dialysis 
10. The trial results were so impressive that rHuEPO was approved for human use in patients with 
chronic renal failure by the Food and Drug Administration (FDA) in June 1989 9, 11. 
Erythropoietin-stimulating agents (ESAs) are given by injection to stimulate red cell production and 
to treat anaemia. Clinical trials have demonstrated a dose-–response relationship between 
erythropoietin and red blood cell expansion 12. They are commercially available in several forms. 
The first- generation ESAs such as Eepoetin-? alfa and epoetin-? beta are recombinant 
erythropoietin analogues, each consisting of 165 amino acids but differ only in their glycosylation. 
Darbepoetin-? alfa, a second- generation ESA, is a hyperglycosylated derivative of Eepoetin. It has 
a longer half-life and, therefore, may be administered less frequently than Eepoetin. Although these 
rHuEPOs act on the same erythropoietin receptor, there are some variations on the degree of 
glycosylation which is responsible for the differences in pharmacokinetics and pharmacodynamics 
between them. The newer third- generation ESAs are chemically synthesiszed, continuous 
erythrocyte receptor activators (CERA), with an even longer half- life than darbepoietin 13, 14. 
The FDA has now extended approval of these agents for the treatment of anaemia resulting from a 
number of causes. These include chronic kidney failure, chemotherapy and certain treatments for 
Hhuman Iimmunodeficiency Vvirus (HIV). It is also used to reduce the number of blood 
transfusions during and after major surgery and in patients who refuse to have an allogeneic blood 
transfusionABT for religious reasons such as Jehovah’'s Witness. The rRHuEPO used for these 
indications has been described as a ‘promising blood-saving technique’ 15. Preoperative rHuEPO 
gained regulatory approval in 1996 to reduce the need for ABT in anaemic patients (pre-treatment 
Hb of 10 g/dL to 13 g/dL) undergoing major surgery 16. It has been (along with iron, vitamin B12 
and folic acid) recommended (along with iron, vitamin B12 and folic acid) as a specific medication 
‘'that should be used instead of blood transfusion’', if the clinical condition of the patient permits 
sufficient time to promote erythropoiesis 11. The rRhuEPO has also been approved for use in 
patients undergoing autologous donation in Japan, Europe and Canada since 1993, 1994 and 1996,
respectively, and for perioperative adjuvant therapy without autologous donation in Canada and the 
United States since 1996 17. 
Other situations relevant to the perioperative period where ESAs have been used, is to treat the 
anaemia associated with critically ill patients in the intensive care unit. Despite earlier trials 
suggesting a small decrease in ABT after administration of ESAs, a more recent multicenter trial, 
conducted after the more widespread use of restrictive transfusion triggers, did not show a 
significant reduction in ABT use 18. Trials have also been conducted in cardiac patients with acute 
ST elevation myocardial infarction with the aim of reducing infarct size and improving 
cardiovascular outcomes. Although these have produced positive outcomes in animal studies, so far 
there have not been any conclusive studies to confirm these effects in the human population 19. 
The therapeutic effect of ESAs involves counteracting the antiproliferative effects of cytokines 
along with the stimulation of iron uptake and heme biosynthesis in erythroid progenitor cells. (see 
Section 1.1).
There are many approved as well as off-label uses of ESAs. The nature of the [CE5]anaemia they are 
treating and these range from chronic use such as to treat the anaemia of chronic renal failure as 
well as episodic use which would include its use to treat the anaemia of critical illness and 
3. Regimes of perioperative rHuEPO use 
Preoperative administration of rHuEPO is effective in treating anaemia by increasing the 
erythrocyte mass and autologous donation volumes while maintaining a higher haematocrit (Hct) 
20. Consequently, it can be administered to assist with autologous donation or prior to elective 
surgery in patients who do not predonate. The beneficial effect of rHuEPO among patients 
participating in preoperative autologous blood donation programmes and for the preoperative 
preparation of patients has been previously reported. Early clinical trials of rHuEPO therapy in the 
setting of autologous donation provided further important information regarding clinical safety, 
rHuEPO dose, and erythropoietin response. Later trials of perioperative rHuEPO therapy without 
autologous donation then provided data on efficacy (reduced allogeneic blood exposure) that led to 
approval of rHuEPO in patients undergoing surgery. Factors that influence the response to rHuEPO 
include the dose and timing of treatment, combined administration of iron and baseline 
Hbhaemoglobin concentration 21, 22. 
3.1 Dose and timing of treatment 
The effect of rHuEPO is rapid. Within 2 to 3 days, a sustained rise in the reticulocyte index is seen 
and the Hcthaematocrit begins to increase. The equivalent of one unit of blood is produced by day 
7, and the equivalent of 5 units is produced by day 28 20. Although several different preoperative 
regimens have been described, the regimen approved by the US FDA consists of four subcutaneous
(s.c.) injections of epoetin-? alfa, 600 U/kg of body weight, administered at 3, 2 and 1one week 
before surgery and again on the day of surgery 23. Weekly doses of rHuEPO are as effective as 
daily administration but are less expensive. Initiating therapy with a single weekly dose would seem 
logical, especially if therapy is commenced well before surgery 20. 
The minimal effective rHuEPO dose required to reduce ABT rate in surgical patients is unknown, 
especially when administered together with iron, and this is reflected in the huge range of dose 
regimes employed by different studies. Protocols used vary from a single large dose of rHuEPO 
given 1one day preoperatively 24 and a subsequent smaller dose administered at the time of surgery 
25, to multiple doses given at weekly intervals over a period of 3 to 4 weeks preoperatively 
26,27,28. Some protocols extend into the post-operative period, whilest daily regimes administered 
from up to 10 days preoperatively have also been used 29,30,31,32,33,34,35,36. The individual 
single dose was higher in patients undergoing weekly treatment compared to those undergoing daily 
treatments, with the majority of those on weekly treatment having 40,000 IU/ per week and those 
on daily treatments receiving between 10,000 IU and 21,000 IU/ daily. Some were based on weight,
while others were a set dose irrespective of any other factors. Total dose is generally higher and the
duration of treatment shorter in patients treated daily compared with those treated weekly. 
3.2 Route of administration 
Both the intravenous (i.v.) and subcutaneous (s.c.) routes can be used to deliver rHuEPO to patients 
with renal impairment. The circulating half-life of rHuEPO is 6 to 8 hours, with significant inter-
individual variations in plasma levels 20. Clinical studies have demonstrated that the s.c. route 
offers a few advantages over i.v. 9, 37, 38. Both i.v.Intravenous and s.c. administrations of 
rHuEPO show substantial differences in their pharmacokinetics. Levels remain elevated longer after 
s.c. (48 hours) than after i.v. administration (18 – 24 hours), although peak levels are not as high. 
The sustained serum levels associated with s.c. dosing are more physiological and, therefore, more 
effectively stimulate erythropoiesis 9, 20. This pharmacokinetic difference may explain why the 
majority of studies chose a rHuEPO dosing strategy using the s.c. method. It is difficult then to 
evaluate the relative efficacy of either i.v. or s.c. methods. 
3.3 Co-administration of iron 
Iron deficiency is considered to be the most important cause of an inadequate response to ESAs. 
Erythropoietin- stimulated erythropoiesis is independent of age and gender, and the variability in 
response among patients is most likely attributable to iron -restricted erythropoiesis 17. Absolute 
iron deficiency, where total body iron stores are depleted, or functional iron deficiency can occur. 
The latter, with normal ferritin levels but low transferrin saturation, is a state which occurs when 
increased erythron iron requirements exceed the available supply of iron. This inability to mobilize 
iron stores rapidly enough develops under conditions of intense erythropoiesis such as during 
treatment with ESAs, and in these cases, supplementary iron may improve the response to ESAs 
39. Iron deficiency may blunt the response to EPO[CE6] or delay recovery from postoperative 
anaemia 40. The maximal effect of rHuEPO injections is usually only achieved when patients’' iron 
stores are adequate 41. 
It has been demonstrated that the use of i.v. iron, with or without rHuEPO, reduced the need for
allogeneic blood transfusionABTs, but stimulation of erythropoiesis seemed to be more pronounced 
among patients also receiving rHuEPO. For these reasons, it has been recommended that rHuEPO 
therapy is supported by supplementary iron either orally or intravenously. Oral iron is usually 
effective but i.v. supplementation should be considered for patients with low iron stores, those with 
a poor initial response to rHuEPO therapy or those who demonstrate increasing evidence of iron 
deficiency with treatment 20. Infusion of iron should take place two to three times weekly for 3 to 4 
weeks. This treatment can be administered to all patients to prevent iron-deficiency during 
erythropoiesis 42. Whilest the majority of studies combined treatment with iron, patients were 
predominantly treated with oral iron rather than i.v. 
However, the use of iron supplementation in anaemia is associated with potentially deleterious 
effects and is therefore controversial. Iron is an essential nutrient for proliferating organisms and 
has been linked to increased risk of developing bacteraemia. It is also associated with the formation 
of oxidative free radicals which can cause tissue damage and may also have immune modulation 
immunomodulatory effects[CE7] 43. 
4. Evidence for of the efficacy of ESA use 
A search was performed using PubUBMedED and OvidVID MEDLINE to identify all articles with 
erythropoietin as a text word. All the titles and abstracts found were examined for studies 
evaluating the use of, as well as safety and efficacy of ESAerythropoiesis stimulating agents in the 
perioperative setting. Studies were included if they were published in English between January 
1993 and June 2013. Only randomiszed trials were included in this part of the review. Studies 
involving children and preoperative autologous blood donation were excluded. Of the 14 published 
studies included (see Table 1), the largest number of trials was in orthopaedic surgery, particularly 
joint replacement procedures, with the remaining trials in gastrointestinal cancer surgery 
29,30,31,32,33 and cardiac surgery. All were randomiszed and included eight double-blind, two 
single-blind and four open-label studies. The majority of primary outcomes in these trials were the 
need for intraoperative blood transfusion, mean number of units of blood transfused, 
Hbhaemoglobin concentrations, Hcthaematocrit levels and reticulocyte counts. Others included 
length of hospital stay and deep venous thrombosis (DVT) detected. 
On the whole, there were variations in dosage regimes and length of treatment duration between the 
different types of surgery. The studies looking at orthopaedic surgery generally had a weekly or 
daily treatment protocol that involved longer treatment duration and enrolled a larger number of 
patients than either cardiac or colorectal cancer surgery. In all the studies, either a minimal 
Hbhaemoglobin or Hcthaematocrit was required for inclusion. Where Hbhaemoglobin was part of 
the inclusion criteria, this ranged from above > 8.5 g/dL to 10 g/dL to below mainly < 13.5 g/dL. 
Two studies did set higher Hbhaemoglobin levels at 14.5 g/dL 43 and 16 g/dL 34 and for those that 
used Hcthaematocrit, this was set at above 42 28, 36. Most benefit was found in patients with a 
baseline Hbhaemoglobin of between 10 and 13 g/dL. Where stated, all studies excluded patients 
with uncontrolled hypertension and history of thromboembolism. 
There were few standard transfusion triggers and often relied on clinical judgement of both 
surgeons and anaesthetists and subjective symptoms reported by patients, whilest several adopted a 
clinical measure such as Hbhaemoglobin level, but this ranged from 7.5 g/dL to 11 g/dL. A 
restrictive transfusion trigger has been shown to be unlikely to be associated with an increased 
incidence of silent myocardial ischaemia or longer hospital stay, but may result in a significant 
reduction in ABT rate. 
Three of the included studies undertaken in patients undergoing orthopaedic procedures and one in 
colorectal cancer surgery randomizsed patients into 3 three groups; 2 two treatment groups along 
with a control group 33. The 2 two treatment groups differed in dosage of rHuEPO used –; a higher 
and lower dose was studied. 
Preoperative administration of rHuEPO was shown to reduce allogeneic blood exposure in 
individuals undergoing elective surgical procedures associated with significant blood loss such as 
joint replacement, cardiac and oncological surgery in all except three studies 29,30,31. All the 
studies showing a negative correlation with ABT rate were in patients undergoing colorectal 
surgery. In all those studies which showed a significant reduction of ABT associated with rHuEPO 
use, there was also a significant reduction in the mean number of units transfused in the treatment 
groups. In all papers that evaluated this as the primary outcome, there was also a significant 
increase in reticulocyte count and Hcthaematocrit. 
In Among the 4 four studies that had 2 two treatment groups as well as a control group, 3 three of 
thesestudies showed a significant reduction in ABT in both treatment groups. In one of these 
studies, there was more reduction in ABT in the lower- dose group compared to the higher dose 28. 
The remaining one study of the 4, despite showing a reduction of ABT use in both treatment 
groups, was only significant with the higher dose of rHuEPO 33. 
4.1 Colorectal cancer surgery 
There were 5 five randomiszed trials looking at the use of rHuEPO in colorectal cancer surgery. Of 
these, three studies 29,30,31 did not show a significant difference in blood transfusion rates 
between treatment group and control. One of these three studies did, however, show a significant 
reduction in the mean number of units transfused in the treatment group 31. In comparison, the two 
other studies 32, 33 showed a significant reduction in transfusion rates in the rHuEPO group as 
well as increased Hbhaemoglobin levels. The study that had 2 two treatment groups with a high-
dose and low -dose regime only showed a significant reduction in ABT in those treated with a 
higher dose of EPO 33. 
The rHuEPORecombinant human erythropoietin needs to be given in combination with iron, and 
this is particularly important in patients undergoing cancer surgery who may be iron- deficient, 
although it has been suggested that the benefit of supplemental iron may be less in oncology 
patients due to the decreased ability for of erythropoiesis which could be related to other factors 
associated with malignancy. All studies involved the co-administration of iron and in all but one,43,
this was done as oral supplementation. The studies that used i.v. iron showed a significant reduction 
in ABT in the treatment group. It appears that oncology patients respond better to i.v. than to oral 
iron supplementation in chemotherapy-induced anaemia treated with rHuEPO. This is thought[CE8]
to be due to an absolute iron deficiency due tobecause of continuousing external losses externally
but and also due to decreased gastrointestinal absorption and iron sequestration caused by increased 
expression of hepcidin that can occur in oncology patients, as well as poor compliance 8, 44. Due 
Owing to the shorter duration of treatment prior to surgery necessitated by the urgency of these 
procedures, the duration of iron treatment was has also been short. 
The low transfusion trigger was set at a Hbhaemoglobin level of 7.5 g/dlL and the iron deficiency in 
almost all patients in one of the studies may have contributed to the generally low transfusion 
frequency leading to a negative result 30. Another possibility for the negative results in this group 
was that rHuEPO was not adequately effective in stimulating haematopoiesis in patients with 
tumour-induced anaemia and colorectal cancer 29. The nature of cancer surgery means that any 
unnecessary delay would be unethical which normally means that there is a shorter preoperative 
time and, therefore, a shorter period of time to initiate rHuEPO treatment. In light of this, the 
treatment start date in these studies ranged from 4 to 10 days prior to surgery. A daily treatment 
regime was used in all study protocols. This, in part, may also have contributed to the heterogeneity 
of the results. The differences[CE9] with between the 2 two studies which showed a reduction of 
blood transfusion with ESA treatment is that the overall dosage of ESA administered over the 
treatment period was higher –; one study had the dosage of ESA for 10 days daily and the other for 
7 days daily preoperatively 24, 36, 43. 
4.2 Cardiac surgery 
Despite all study protocols being different with regards to dosage, interval of dosing and length of 
time of treatment duration, they all showed a significant reduction in ABT in the treatment group as 
well as significant reduction in mean units of blood transfused. 
4.3 Orthopaedic surgery 
All these studies used relatively large sample sizes, ranging from 194 patients in one study to 695 
patients in another 26. All showed a significant reduction in ABT in the ESA treatment group with 
several also showing a significant reduction in mean units of blood transfused in the ESA group. 
Three studies utiliszed 2two treatment groups with a lower and higher dose of ESA and all showed 
a significant reduction in ABT in both ESA treatment groups. Dosage regimes varied from single 
dose to daily and weekly regimes. Total duration of treatment ranged from one single dose to 4 
weeks. 
5. Safety of erythropoietin in perioperative use
The majority of studies involving the use of perioperative erythropoietin in patients undergoing 
surgery were targeted at efficacy which was reflected in the primary end points being reduction in 
ABT or change in other haematological parameters. Perioperative administration of ESAs to 
surgical patients is thought to have few adverse side effects, because it is a short-term treatment and 
contra-indicated for patients with co-morbidities that may predispose to these side-effects. These 
include uncontrolled arterial hypertension, previous acute myocardial infarction or stroke, unstable 
angina and severe carotid stenosis and are usually cited as exclusion criteria in these studies. Doses
used in perioperative treatment tend to be lower than that which have been used conventionally in 
the past and also for a shorter duration of time. Due Owing to the nature of expected surgical blood 
loss, the rise in Hb is not sustained. 
Trials did report adverse effects in their sample populations including deep venous thrombosis 
(DVT), hypertension, infection, anastomotic breakdown and death. However, due to the low 
incidence of such events in the studies, no clear correlation with rHuEPO treatment could be made. 
The rRhuEPO was also withheld in patients who developed any of these adverse events during the 
study period. A concern for EPO use is the development of thrombotic complications associated 
with the higher Hcthaematocrit resulting from EPO therapy. Thrombotic and vascular events, 
including myocardial infarction, angina, deep vein thrombosis, superficial phlebitis, and peripheral 
arterial thrombosis are associated with rapid increases in the Hbhaemoglobin level and the 
Hcthaematocrit and are of special concern in patients who are managed with EPO. None of the 
studies clearly stated whether anticoagulation prophylaxis was routinely used in their sample 
population. 
The safety effects of rHuEPO have been more extensively studied in other non surgical patient 
populations. Three large randomiszed controlled trials, the Normal Haematocrit Study 45, the 
Correction of Hemoglobin and Outcomes in Renal Insufficiency (CHOIR) Trial 46 and The Trial to 
Reduce Cardiovascular Events with Aranesp Therapy (TREAT)47 46 involved patients with 
anaemia and chronic kidney disease. These studies showed that the use of ESAs to achieve a higher 
Hbhaemoglobin level rather than partial correction of anaemia, which is the most common use of 
ESAs in this population, was associated with significantly increased adverse events including non
fatal and fatal myocardial infarction, non-fatal and fatal stroke, death and thromboembolic events. 
In fact, the results were so conclusive that 2 two of the studies were halted early. In these studies,
the dose of ESA was adjusted and increased if the target Hb was not achieved during monitoring. A 
review of these studies suggested that the increased incidence of adverse events may be related to 
the rapidity of increase in Hbhaemoglobin concentration and an overshoot of target concentration 
which may have been due to aggressive dosing. Another possibility was that these adverse effects 
may be due to some other consequence of ESAs such as trophic effects on vascular endothelial or 
smooth muscle cells 48. 
Studies of the use of ESAs in critically ill patients showed that the proportion of patients who 
experienced thrombotic events was significantly greater with rHuEPO than placebo. However, the 
risk for of thrombotic events was significantly increased in patients who did not receive heparin at 
baseline but not among patients who did receive heparin at baseline 18. 
In a large multicentere trial of 680 surgical patients scheduled for elective spine surgery, blood 
transfusion and patient outcomes were compared for ESA and placebo-treated cohorts. These 
patients did not receive anticoagulation prophylaxis for thrombotic adverse events. This study 
documented a higher incidence of deep vein thrombosis of 4.7% in the study group was 4.7% 
compared to 2.1% in control 2.1%, with the upper confidence limit for the between-group 
difference being 5.4%. This exceeded the predefined boundary of 4% that was required to 
demonstrate noninferiority 49. 
In a small- scale, double-blind, placebo- controlled study involving 30 healthy male volunteers who 
were given rHuEPO, there was a moderate stimulation of thrombopoiesis and this has been 
suggested to be increased by 15%. However, rHuEPO was also thought to cause increased platelet 
reactivity and a thrombogenic effect on the newly synthesized platelets, which may lead to 
increased thrombotic events 12. 
Hypertension is commonly associated with long-term rHuEPO therapy in patients with chronic 
renal failure. Although there seems to be a low risk of precipitating hypertension during short-
course preoperative rHuEPO therapy, there have been reports of individual patients without prior 
history developing hypertension during such treatment. Despite the finding of hypertension in some 
of the patients in these studies, there was no clear correlation with rHuEPO therapy. 
There is uncertainty about the potential side effects of erythropoietin analogues in anemic 
patientseople with anaemia who are receiving treatment for cancer. The European Medicines 
Agency ‘has recently reviewed the safety of erythropoietin analogues based on new data from both 
published and unpublished studies. These studies suggest an increased risk of serious 
cardiovascular complications in people with chronic renal failure and a possible effect on tumour 
progression in people with cancer’ 13. However, the risk/benefit of ESAs has recently been 
questioned based upon individual reports and meta-analyses showing that these agents are 
associated with an increased risk of mortality when chronically administered to patients with 
advanced/metastatic cancers 50. Erythropoietin receptors are found on several malignant lines and 
can increase tumour recurrence rates. 
Although the positive short-term effects of ESA therapy with ESAs on the correction of anaemia 
and avoidance of blood transfusions are well documented, few data are available on possible effects 
on the course of underlying disease, particularly since ESAs can exert additional biological effects 
including interference with the signal transduction cascade of cytokines. 
6. Conclusions
Minimiszing allogeneic blood transfusionABT should be a high priority of any health care delivery 
system. Transfusions associated with perioperative care represent a significant proportion of blood 
consumed. The concept of patient blood management has recently been described and was adopted 
by the World Health Organiszation in 2010 as a principle to improve transfusion safety. It refers to 
pre-empting and significantly reducing the need for transfusion by addressing anaemia, blood loss 
and hypoxia as modifiable risk factors. It comprises three main factors: detection and correction of 
preoperative anaemia, minimiszing perioperative blood loss and optimiszing the patient’'s 
physiological tolerance to anaemia 50. It can play a significant role in negating preoperative 
anaemia and augmenting the quantity of blood available for autologous transfusion. 
The effect of ESAs on transfusion requirements in cancer surgery patients remains uncertain, 
although, in patients who underwent orthopaedic surgery, treatment with preoperative ESA reduced 
both the use and rate of blood transfusion. It is clear that the use of perioperative rHuEPO does 
reduce the number of transfusions, reduce the mean number of transfusions given, increase the 
reticulocyte count and increase Hbhaemoglobin levels. At present, there is no clear optimal strategy 
with respect to dose, timing and length of treatment. The subcutaneous s.c. route is commonly used 
and has pharmacokinetic advantages. Perioperative rHuEPO therapy seems to be associated with a 
low incidence of complications, although larger studies are necessary to define this more clearly. 
There is an apparent risk of deep vein thrombosis but the risk can be ameliorated with the judicious 
use of anticoagulation. 
Despite being theoretically attractive, the uptake of perioperative rHuEPO use has been slow. One 
reason for the limited use of preoperative rHuEPO in clinical practice may be the impracticality of 
the dosing schedule as recommended by efficacy trials, particularly with a required lead- time of 4 
weeks. Another reason may be the high-cost of the recommended dosage. Complications from 
ABTallogeneic blood transfusion can be serious and expensive but are not necessarily linearly 
related to the numbers of units transfused and, consequently, the cost savings gained from averting 
a disaster are difficult to quantify. Other effects such as immune suppression are even less tangible.
The ‘true’ cost- effectiveness of EPO treatment is thus difficult to calculate and may be a hindrance 
to more widespread adoption. 
7. Expert opinion 
There is evidence that the perioperative use of ESAs can reduce the need for ABTallogeneic blood 
transfusions in patients undergoing major surgery with high anticipated high blood loss. With the 
current drive to improve transfusion safety by modifying risk factors such as anaemia, blood loss 
and hypoxia, the targeting of anaemic patients preoperatively and the use of ESAs to stimulate 
erythropoiesis have been shown to have beneficial effects. The increase in haematological 
parameters may improve a patient’'s status in order to optimisze post-operative rehabilitation, which 
can in turn lead to reduced hospital stay and improved quality of life. 
Currently, the use of perioperative ESAs in surgery with anticipated high blood loss does not appear 
to be widely adopted. Whilest the evidence exists for the use of rHuEPO in the perioperative 
setting, it has yet to be quantified whether other types of ESAs may also be effective. Development 
in of the newer ESAs with their more favourable pharmacokinetic profiles may mean decreased 
frequency of administration and may therefore improve the practicalities of incorporating ESAs into 
a perioperative programme. 
Many of the studies were in small numbers of patients and it is difficult to adequately assess 
efficacy as an end point. Safety of ESAs have mainly come from the large- scale studies in anaemic 
patients with chronic renal disease which have shown an increased risk of non fatal and fatal 
myocardial infarction, non-fatal and fatal stroke, death and thromboembolic events. It is unclear 
though whether these results can be extrapolated to the perioperative population. There are many 
differences between these 2 two groups of patients; the higher levels of Hb are not maintained as 
significant blood loss is expected intraoperatively in the perioperative group and the duration is of
treatment is much shorter with much lower cumulative doses. The elective surgical population will 
also have a better functional and physiological baseline. 
Well- designed prospective randomized controlled trialRCTs on a larger scale are needed to address 
dose, type of ESA, timing and duration of administration in order for optimal dosing strategies to be 
formulated. The adverse event reporting could also be more accurate. 
Once an optimal dosing strategy can be agreed, it would be useful to undertake cost- effectiveness 
studies; there are not only the costs associated with the treatment drug itself, but also there are
administration and screening costs, but these may be ameliorated by the cost savings of reduction in 
hospital stay as well as improvement in quality of life. 
An important area for future research may be to explore further the pleiotropic effects of ESAs as 
well as to investigate the effects of ESAs at the cellular level as possible mechanisms to exert their
adverse effects. 
Given the awareness of risks and complications associated with ABTallogeneic blood transfusions, 
the use of perioperative ESA in surgery with anticipated high blood loss, is an important 
consideration. 
Article highlights. 
Benefits of perioperative erythropoiesis stimulating agents (ESAs) include an increase in 
Hcthaematocrit and reticulocyte counts which lead to a reduction in ABTallogeneic blood 
transfusions. 
Reduction in ABTallogeneic blood transfusion hasve been consistently shown in randomized trials 
of patients undergoing orthopaedic and cardiac surgery. 
Use of perioperative ESAs in cancer patients hasve not consistently demonstrated a reduction in 
ABTallogeneic blood transfusion use. 
Iron deficiency can reduce the efficacy of ESAs. 
The optimal dosing strategies for perioperative use have not yet been defined. 
ESA use in chronic renal failure patients with anaemia have shown an increase in adverse events 
when aiming for normalization of Hbhaemoglobin levels rather than partial correction. 
Adverse events associated with short -term perioperative use have not yet been quantified. 
This box summarizes key points contained in the article.
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Table 1. Summary of the clinic trials included in this review. 
Type of 
surgery 
Type of 
blinding
No. of 
patients
Start 
Hb 
ESA 
used 
Treatment 
duration 
prior to 
surgery 
Total 
duration 
treatment
Administration
frequency 
Fe 
used 
C
t
Orthopaedic – 
bilateral knee 
replacements)
25  
oOpen 108 Hb 
> 10 
EPO B 
scs.c.
Once 
during 
surgery 
Single 
dose 
Single dose Iv i.v. 
Fe 
sucrose
1 unit
69 g/L
betwe
Orthopaedic – 
primary or 
revision hip 34 
dDouble 320 Hb 
11 – 
16 
EPO 
s.c.sc
10 days 14 days dDaily Oral 
Fe 
sulfate 
Clinic
practi
volum
intrao
9/dL p
opera
Orthopaedic – 
all elective 
major 26 
oOpen 695 Hb 
10 – 
13 
EPO A 
s.c.sc
21 days 22 days wWeekly Oral 
Fe 
Hb <
Orthopaedic – 
major elective 
35  
dDouble 200 EPO 
s.c.sc
(3 
groups)
10 days 15 days dDaily Oral 
Fe 
Discr
surge
0.27
Orthopaedic – 
total hip 
arthroplasty 27
Double  201 Hb 
9.8 
– 
13.7 
EPO A 
s.c.sc
(3 gps) 
4 weeks 4 weeks Wweekly Oral 
Fe 
Discr
surge
Orthopaedic – 
knee and ankle 
28  
oOpen 194 Hct 
< 
42%
EPO B 
s.c.sc
(3 gps) 
3 – -4 
weeks 
3 – -4 
weeks 
Wweekly Oral 
Fe 
Discr
surge
Hb <
Cancer – GI 
gastrointestinal 
tract 32  
dDouble 63 Hb 
8.5 
– 13 
EPO A 
s.c.sc
7 days  14 days Ddaily Iv i.v. 
Fe 
Hb </
Cancer – 
colorectal 
surgery 33  
oOpen 204 Hb 
9 – 
12 
EPO A 
s.c.sc
(3 gps) 
10 days 12 days Ddaily Oral 
Fe 
Periop
loss >
heart/
oOthe
mlL. 
Hb, 1
poor p
featur
g/dL
Cancer – 
colorectal 29  
dDouble 30 Hb 
9 – 
13 
EPO 
s.c.sc
10 days 13 days Every 2 days Oral 
Fe 
? 9 g/
Cancer – right 
hemicolectomy 
30  
dDouble 109 Hb 
8.5 
– 
13.5 
EPO B 
s.c.sc
5 – 10 
days 
10 – 15 
days 
Ddaily Oral 
Fe 
Hb <
Cancer – 
colorectal 31  
dDouble 81 Hb 
</= 
8.5 
EPO A 
s.c.sc
4 days 8 days Ddaily Oral 
Fe 
Discr
attend
anaes
Cardiac – 
valvular 24 
Ssingle 74 Hb 
< 12 
F 
and 
Hb 
< 13 
EPO Iv 16 – 24 hr
prior to 
surgery 
Single 
dose 
Single dose Iv i.v. 
Fe 
sucrose
Hb < 
CPB 
after C
opera
M 
Cardiac – off 
pump CABG 
43  
Ssingle 320 Hb 
< 
14.5 
EPO 
s.c.sc
2 days 5 days Ddaily - Hb <
Cardiac – open 
heart 36 
Ddouble 76 Hct 
< 
0.45 
EPO B 
ivi.v.
14 days 14 days 5 doses Oral 
Fe 
sulfate 
CPB:
posto
8.5 g/
0.26 
ABT: Allogeneic blood transfusion; CABG: Coronary artery bypass graft; CPB: Cardiopulmonary 
bypass; EPO A: Epoetin-? alfa; EPO B: Epoetin-? beta; ESA: Erythropoiesis- stimulating agents; 
Fe: Iron; Hb: Haemoglobin; Hct: Haemocrit; HD: High dose; i.v.: Intravenous; LD: Low dose; s.c.: 
Subcutaneous. 
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